Skip to the content
 

Publications

Clinical Pharmacology Unit

Department of Epidemiology & Preventive Medicine

2007

  • Ritzema J, Melton IC, Richards AM, Crozier IG, Frampton C, Doughty RN, Whiting J, Kar S, Eigler N, Krum H, Abraham WT, Troughton RW.  Direct left atrial pressure monitoring in ambulatory heart failure patients: initial experience with a new permanent implantable device.  Circulation 2007;116:2952-2959.
  • Tobing D, French J, Varigos J, Meehan A, Billah B, Krum H for the post-MI audit group.  Do patients with heart failure appropriately undergo invasive procedures post-myocardial infarction?  Results from a prospective multicentre study.  Int Med J 2007; 1-7 (in press)
  • Szollosi I, Krum H, Kaye D, Naughton MT.  Sleep apnea in heart failure increases heart rate variability and sympathetic dominance.  Sleep 2007;30(11):1509-1514.
  • McMurray J, Teerlink JR, Cotter G, Bourge RC, Cleland JGF, Jondeau G, Krum H, Metra M, O’Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I for the VERITAS investigators.  Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure.  The VERITAS randomized controlled trials.  JAMA 2007;298(17):2009-2019.
  • Wein L, Wein S, Haas SJ, Shaw J, Krum H.  Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients.  Arch Intern Med 2007;167(14):1476-1486.
  • W Kemp, S Roberts, H Krum.  Increased circulating urotensin II in cirrhosis: potential implications in liver disease.  Peptides 2007 (in press)
  • Connelly KA, Kelly DJ, Zhang Y, Prior DL, Martin J, Cox AJ, Thai K, Feneley MP, Tsoporis J, White KE, Krum H, Gilbert RE.  Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat.  Cardiovasc Research 2007;76:280-291.
  • Kelly DJ, Zhang Y, Connelly K, Cox AJ, Martin J, Krum H, Gilbert RE.  Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy.  Am J Physiol Heart Circ Physiol 2007;293:H2860-H2869.
  • R Clarke, J Yallop, L Piterman, J Croucher, A Tonkin, S Stewart, H Krum on behalf of the CHAT study team.  Adherence, adaptation and acceptance of elderly chronic heart failure patients to receiving healthcare via telephone-monitoring.  Eur J Heart Fail 2007;9:1104-1111.
  • Kemp W, Krum H, Colman J, Bailey M, Yandle T, Richards M, Roberts S.  Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension.  Liver International 2007 Nov;27(9):1232-9.
  • Martin J, Krum H.  Statins and clinical outcomes in heart failure.  Clinical Science 2007;113:119-127.
  • Phrommintikul A, Haas SJ, Elsik M, Krum H.  Target haemoglobin concentrations in chronic kidney disease - Authors' reply. Lancet 2007;369:1516-1517.
  • Clark R, Eckert K, Stewart S, Phillips S, Yallop J, Tonkin A, Krum H.  Rural and urban differentials in primary care heart failure management: new data from the CASE study.  Med J Aust 2007;186:441-445.
  • Pepe S, Marasco SF, Haas SJ, Sheeran FL, Krum H, Rosenfeldt FL.  Coenzyme Q10 in cardiovascular disease.  Mitochondrion 2007;7S:S154-S167.
  • Williams AD, Carey MF, Selig S, Hayes A, Krum H, Patterson J, Toia D, Hare DL.  Circuit resistance training in chronic heart failure improves skeletal muscle mitochondrial ATP production rate – a randomized controlled trial.  J Card Fail 2007;13:79-85.
  • Krum H, Kemp W.  Therapeutic potential of blockade of the urotensin II system in systemic hypertension.  Curr Hypertens Rep 2007;Mar 9(1):53-58.
  • Yancy CW, Krum H, Massie BM, Silver MA, Stevenson LW, Cheng M, Kim SS, Evans R for the FUSION II Investigators.  The second follow-up serial infusions of nesiritide (FUSION II) trial for advanced heart failure: Study rationale and design.  Am Heart J 2007;153:478-84.
  • Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong J-Y, Watts GF.  Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials.  J Hum Hyper 2007;21:297-306.
  • Phrommintikul A, Haas SJ, Elsik M, Krum H.  Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis.  Lancet 2007;369:381-388.
  • Elsik M, Krum H.  Should beta blockers remain first-line drugs for hypertension?  Aust Prescriber 2007;30:18-21.
  • Haas SJ, Hill R, Krum H, Liew D, Tonkin A, Demos L, Stephan K, McNeil J.  Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003.  Drug Safety 2007;30:47-57.
  • Kaye DM, Krum H.  Drug discovery for congestive heart failure: New era of pharmacological therapies or end of the pipeline?  Nature Rev Drug Discov 2007;6(2):127-139.
  • Krum H, Gilbert R. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders. J Hypertension 2007;25:25-35.
  • Krum H, Ashton E, Reid C, Kalff V, Rogers J, Amarena J, Singh B, Tonkin A.  Double-blind, randomized placebo-controlled, parallel-group, multicenter, phase III study to assess the impact of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.  J Card Fail. 2007;13:1-7.
  • Szramka M, Harriss L, Ninnio D, Windebank J, Brack J, Skiba M, Krum H. The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease Int J Cardiol  2007;117:287-291.
  • Krum H, Bailey M, Lechat P, Verkenne P, Anker S. Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS II Cardiology 2007;108:28-34.

2006

  • Yallop J, Chan B, Piterman L, Tonkin A, Forbes A, Davidson P, Clark R, Halcomb E, Nangle A, Stewart S, Croucher J, Krum H on behalf of the CHAT Study Group.  The Chronic Heart-failure Assistance by Telephone (CHAT) Study: Assessment of telephone support for vulnerable patients with chronic disease.  Asia Pacific Journal of Family Medicine 2006;5(2).
  • Macdonald PS, Hill J, Krum H for the COLA II Investigators.  The impact of baseline heart rate and blood pressure on the tolerability of carvedilol in the elderly: The COLA II study.  Am J Cardiovascular Drugs 2006;6(6):401-405.
  • Ajani AE, Marwick TH, Krum H.  Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure.  Cardiovasc Revascularization Medicine 2006;7:234-236.
  • Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L for the MEDAL Steering Committee.  Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.  Lancet 2006; 368:1771-81.
  • Pitt B, Ferrari R, Gheorghiade M, Van Veldhuisen DJ, Krum H, McMurray J, Lopez-Sendon J.  Aldosterone blockade in post-acute myocardial infarction heart failure.  Clin Cardiol 2006; 29:434-438.
  • Krum H, Jelinek M, Stewart S, Sindone A, Atherton J, Hawkes A, Foreman R. Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. Med J Aust  2006;185:549-56.
  • Krum H, Latini R, Maggioni AP, Anand I, Masson S, Carretta E, Ingrilli F, Pettinati G, Glazer R, Tognoni G, Cohn J.  Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT.  Int J Cardiol 2006 (in press).    
  • Zimmet H, Krum H.  Beta-blockers for treatment of heart failure in the elderly.  J Pharm Pract Res 2006;36:229-233.                                                                                  
  • McClean D, Aragon J, Jamali A, Kar S, Ritzema-Carter J, Troughton R, Krum H, Doughty R, Abraham WT, Whiting JS, Eigler N. Noninvasive calibration of cardiac pressure transducers in patients with heart failure: an aid to implantable hemodynamic monitoring and therapeutic guidance. J Card Fail. 2006;12:568-76
  • Willenheimer R, Krum H, van Veldhuisen DJ, Funck-Brentano C, Erdmann E, Meyer WR; CIBIS III Steering Committee and Investigators. Comment on "Clinical trials update from the European Society of Cardiology meeting 2005: CIBIS-III, by JGF Cleland and others". Eur J Heart Fail. 2006;8:219-20.
  • Krum H, Cameron P.  Diuretics in the treatment of heart failure: Mainstay of therapy or potential hazard? Editorial Comment. J Card Fail. 2006;5:333-335.
  • Krum H, Meehan A, Varigos J, Loane P, Billah B.  Does presence of heart failure alter prescribing of drug therapy following myocardial infarction?  A multicentre study of Australian hospitals.  Med J Aust 2006;185:191-194.
  • Yallop J, Clark R, Chan B, Croucher J, Wilson A, Sellar B, Piterman L, Tonkin A, Krum H.  CHAT--a study of a nurse-led system of care.  Aust Nurs J 2006;14:19.
  • Gilbert R, Krum H, Parker TG. Heart failure: the forgotten complication of diabetes. Metabolic Syndrome Rounds 2006;4:128-130.
  • Ritzema-Carter JLT, Smyth D, Troughton RW, Crozier IG, Melton IC, Richards AM, Eigler N, Whiting J, Kar S, Krum H, Abraham WT. Dynamic myocardial ischemia caused by circumflex artery stenosis detected by a new implantable left atrial pressure monitoring device. Circulation 2006 113: e705 - e706.
  • Gilbert RE, Connelly K, Kelly DJ, Pollock CA, Krum H. Heart failure and nephropathy: catastrophic and inter-related complications of diabetes. CJASN 2006;(1):193-208.
  • Dulin B, Krum H.  Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.  Curr Opin Cardiol. 2006;21:393-399.
  • Aw T-J, Liew D, Tofler GH, Schneider HG, Morel-Kopp M-C, Billah B, Krum H.  Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels?  J Hypertens 2006;24:1979-1984.
  • Ferro A, Gilbert R, Krum H.  Importance of renin in blood pressure regulation and therapeutic potential of renin inhibition.  Int J Clin Practice 2006;60:577-81.
  • Krum H, Stewart S.  Chronic heart failure: time to recognise this major public health problem. Editorial.  Med J Aust 2006;184(4):147-148.
  • Krum H, Ruschitzka F.  ‘Class effect’ amongst cardiac drugs: term of convenience or pharmacological reality? Editorial.  Int J Clin Pract 2006; 60(1):2-5.
  • Krum H, Mohacsi P, Katus HA, Tendera M, Rouleau JL, Fowler MB, Coats AJ, Roecker EB, Packer M.  Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.  Am Heart J  2006;151:55-61.
  • Ajani AE, Szto G, Duffy SJ, Eccleston D, Clark DJ, Lefkovits J, Chew DP, Warren R, Black A, New G, Walton A, Lew R, Shaw J, Horrigan M, Sebastian M, Yan BP, Brennan A, Meehan A, Reid C, Krum H.  The foundation and launch of the Melbourne Interventional Group: A Collaborative Interventional Cardiology Project.  Heart Lung and Circulation 2006;15:44-7.
  • Krum H, Hill J, Fruhwald F, Sharpe C, Abraham G, Zhu J-R, Kragten. Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study.  Eur J Heart Fail 2006;8:302-307.
  • Krum H, Aw J, Haas SJ, Liew D.  Blood Pressure Effects of COX-2 Inhibitors.  J Cardiovasc Pharmacol 2006;47[Suppl 1]:S43-S48.
  • Krum H, Lambert E, Windebank E, Campbell DJ, Esler M. Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension. Am J Physiol Heart Circ Physiol. 2006;290:H1706-12.
  • Connelly KA, Prior DL, Kelly DJ, Feneley MP, Krum H, Gilbert RE.  Load sensitive measures may overestimate global systolic function in the presence of left ventricular hypertrophy: A comparison with load insensitive measures. Am J Physiol Heart Circ Physiol. 2006;290:H1699-705.
  • Krum H.  Eplerenone.  (Letter to Editor)  Aust Prescriber 2006;29:32-33.
  • Boyle AJ, Whitbourn R, Schlict S, Krum H, Kocher A, Nandurkar H, Bergmann S, Daniell M, O’Day J, Skerrett D, Haylock D, Gilbert RE, Itescu S.  Intra-coronary high-dose CD34+ stem cells in patients with chronic ischemic heart disease: A 12-month follow-up.  Int J Cardiology 2006 Apr 28;109(1):21-7.
  • Clark RA, Yallop J, Wickett D, Krum H, Tonkin A, Stewart S. Nursing sans frontières: a three year case study of multistate registration to support nursing practice using information technology. Aust J Adv Nursing. 2006;24:39-45.

2005

  • Liew D, Krum H.  The cardiovascular safety of celecoxib.  Future Cardiol. 2005;1(6) 709-722.
  • Walton AS, Krum H.  The Heartpod implantable heart failure therapy system.  Heart Lung and Circulation 2005;14S:S31-S33.
  • Ajani AE, Szto G, Duffy SJ, Eccleston D, Clark DJ, Lefkovits J, Chew DP, Warren R, Black A, New G, Walton A, Lew R, Shaw J, Horrigan M, Sebastian M, Yan BP, Brennan A, Meehan A, Reid C, Krum H.  The foundation and launch of the Melbourne Interventional Group: A Collaborative Interventional Cardiology Project.  Heart Lung and Circulation 2005 (in press).
  • Xiang G, Seki T, Schuster MD, Witkowski P, Boyle AJ, See F, Martens TP, Kocher A, Sondermeijer H, Krum H, Itescu S. Catalytic Degradation of Vitamin D Up-regulated Protein 1 mRNA Enhances Cardiomyocyte Survival and Prevents Left Ventricular Remodeling after Myocardial Ischemia. J Biol Chem. 2005;280:39394-402.
  •  Krum H, Campbell DJ, Windebank E, Esler M. Effect of angiotensin II receptor blockade on autonomic function in hypertension patients. Am J Physiol Heart Circ Physiol. 2005 (in press)
  •  Krum H, Aw J, Haas SJ, Liew D.  Blood Pressure Effects of COX-2 Inhibitors.  J Cardiovasc Pharmacol 2005 (in press)
  • Connelly KA, Prior DL, Kelly DJ, Feneley MP, Krum H, Gilbert RE. Load sensitive measures may overestimate global systolic function in the presence of left ventricular hypertrophy: A comparison with load insensitive measures. Am J Physiol Heart Circ Physiol. 2005 Nov 4
  • Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, Ponikowski P, Skene A, van de Ven L, Verkenne P, Lechat P.  Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence.  Results of the randomized cardiac insufficiency bisoprolol study (CIBIS) III.  Circulation 2005 Oct 18;112(16):2426-35. Epub 2005 Sep 4.
  • McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs FDR, Krum H, Maggioni A, McKelvie RS, Pina IL, Soler-Soler J, Swedberg K.  Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice. Eur J Heart Fail 2005; 7:710-721.
  • Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J for the EPHESUS Investigators.  Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.  J Am Coll Card 2005; 46: 425-431.
  • Krum H.  The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology.  Guidelines for the diagnosis and treatment of chronic heart failure.  Letter to the editor.  Eur H Journal 2005 Nov;26(22):2472. Epub 2005 Oct 4.
  • Hermann M, Krum H, Ruschitzka F.  To the heart of the matter: Coxibs and smoking (editorial).  Circulation 2005;112(7):941-945.
  • Martin JH, Denver R, Bailey M, Krum H.  In-vitro inhibitory effects of statins on cardiac fibrosis: implications for ventricular remodelling.  Clin Exp Pharm Physiol 2005; 32: 697-701.
  • Boyle AJ, Whitbourn R, Schlicht S, Krum H, Kocher A, Nandurkar H, Bergmann S, Daniell M, O’Day J, Skerrett D, Haylock D, Gilbert RE, Itescu S.  Intra-coronary high-dose CD34+ stem cells in patients with chronic ischemic heart disease: A 12-month follow-up.  Int J Cardiology 2005 (in press)
  • Krum H, Hill J, Fruhwald F, Sharpe C, Abraham G, Zhu J-R, Kragten. Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study.  Eur J Heart Fail 2005 Sep 28; [Epub ahead of print]
  • Krum H. Could risk stratification aid the treatment of patients with acute heart failure (invited commentary) Nature Clinical Practice Cardiovascular Medicine  2005 Jul;2(7):334-5.
  • Krum H, Haas S, Eichhorn E, Ghali J, Gilbert E, Lechat P, Packer M, Roecker E, Verkenne P, Wedel H, Wikstrand J.  Prognostic benefit of beta-blockers in patients not receiving ACE inhibitors.  Eur Heart J  2005;26:2154-2158.
  • Sondermeijer B, Kompa A, Komesaroff P, Krum H.  Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension.  Am J Hypertension 2005;9:1195-1199.
  • Piterman L, Zimmet H, Krum H, Tonkin A, Yallop J.  Chronic heart failure. Optimising care in general practice.  Aust Family Physician 2005;34(7):547-553.
  • Boyle AJ, Kelly DJ, Zhang Y, Cox AJ, Gow RM, Way K, Itescu S, Krum H, Gilbert RE.  Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction.  J Mol Cell Cardiol 2005 Aug;39(2):213-21.
  • Kemp W, Roberts S, Krum H.  Urotensin II: a vascular mediator in health and disease.  Curr Vasc Pharmacol 2005;3:159-168.
  • Dulin BR, Haas SJ, Abraham WT, Krum H.  Do elderly systolic heart failure patient benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials.  Am J Cardiol 2005;95:896-898.
  • Aw J, Haas SJ, Liew D, Krum H.  Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure.  Arch Intern Med 2005;165:490-6.
  • Packer M, McMurrary J, Massie BM, Caspi A, Charlon V, Cohen-Solal A, Kiowski W, Kostuk W, Krum H, Levine B, Rizzon P, Soler J, Swedberg K, Anderson S, Demets DL.  The Research on Endothelin Antagonism in Chronic Heart failure (REACH-1) study group.  Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study.Journal of Cardiac Failure 2005; 11:12-20.
  • Campbell DJ, Krum H, Esler MD.  Losartan increases bradykinin levels in hypertensive humans.  Circulation 2005;111:315-320.
  • Teerlink JR, McMurray JJ, Bourge RC, Cleland JG, Cotter G, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, Van Veldhuisen DJ, Frey A, Rainisio M, Kobrin I; VERITAS Investigators. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J. 2005 Jul;150(1):46-53.
  • See F, Kompa A, Martin J, Lewis DA, Krum H.  Fibrosis as a therapeutic target post-myocardial infarction.  Current Pharmaceutical Design 2005;11:477-487.
  • Martin J, Kelly DJ, Mifsud SA, Zhang Y, Cox AJ, See F, Krum H, Wilkinson-Berka J, Gilbert RE.  Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-β.  Cardiovascular Research 2005;65:694-701.
  • Cameron P, Krum H. Chronic heart failure. Emerg Med Australas. 2005 Apr;17(2):99-101.

2004

  • Connelly K, Kelly DJ, Langham R, Krum H, Gilbert RE.  Drug therapy for the cardiac complications of diabetes.  Drug Discovery Today: Therapeutic Strategies 2004 1(2):195-199.
  • Krum H.  Commentary: Trial finds administering carvedilol in hospital improves treatment adherence for people with heart failure.  Evidence-based Cardiovascular Medicine 2004:8;319-320. 
  • Krum H, Carson P, Farsang C, Maggioni AP, Glazer RD, Aknay N, Chiang YT, Cohn JN. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail. 2004 Dec;6(7):937-45.
  • See F, Kompa A, Krum H.  p38 MAP kinase as a therapeutic target in cardiovascular disease. Drug Discovery Today: Therapeutic Strategies 2004 1(2):149-154.
  • See F, Thomas W, Way K, Tzanidis A, Kompa A, Lewis D, Itescu S, Krum H.  p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol. 2004 Oct 19;44(8):1679-89.
  • Lim M, Honisett S, Sparkes CD, Komesaroff P, Kompa A, Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 2004;109:1212-1214
  • Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, Van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594-602
  • Kompa AR, Thomas WG, See F, Tzanidis A, Hannan RD, Krum H. Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides 2004 Oct;25(10):1783-8
  • Gilbert RE, Douglas S, Krum H. Urotensin II as a novel therapeutic target in the management of cardiorenal disease. Curr Opin Invest Drugs 2004 2004,5:276-282
  • Baruch L, Glazer RD, Aknay N, Vanhaecke J, Heywood JT, Anand I, Krum H, Hester A, Cohn JN.  Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2004;148:951-957.
  •  Krum H. Tolerability of carvedilol in patients with chronic heart failure Am J Cardiol  2004 May 6;93(9A):58B-63B
  • Williams AD, Selig S, Hare DL, Hayes A, Krum H, Patterson J, Geerling RH, Toia D, Carey MF. Reduced exercise tolerance in CHF may be related to factors other than impaired skeletal muscle oxidative capacity. J Cardiac Failure. 2004;10:145-152
  • Rouleau JL, Roecker EB, Tendera M, Mohacsi P, Krum H, Katus HA, Fowler MB, Coats AJ, Castaigne A, Scherhag A, Holcslaw TL, Packer M; Carvedilol Prospective Randomized Cumulative Survival Study Group. Influence of pretreatment systolic blood pressure on the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol. 2004;43:1423-9.
  • Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Anker SD, Amann-Zalan I, Hoersch S, Katus HA.Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation. 2004 Sep 28;110(13):1780-6
  • Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Trawinski J, Amann-Zalan I, Hoersch S, Katus HA. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail. 2004;6:343-50
  • Krum H, Hare D.  Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS III) (letter) Eur Heart J 2004;25:277
  • Liew D, Schneider H, Shaw J, Krum H. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 2004;27:848
  • Willenheimer R, Erdman E, Follath F, Krum H, Ponikowski P, Silke B, van Veldhuisen DJ, van de Ven L, Verkenne P, Lechat P on behalf of the CIBIS III investigators Comparison of treatment initiation with bisoprolol vs enalapril in chronic heart failure patients: rationale and design of CIBIS III. Eur J Heart Failure 2004 Jun;6(4):493-500
  • Peterson GM, Fitzmaurice KD, Naunton M, Vial JH, Stewart K, Krum H. Impact of pharmacist-conducted home visits on the outcomes of lipid-lowering drug therapy. J Clin Pharm Ther. 2004;29:23-30
  • Selig SE, Carey MF, Menzies DG, Patterson J, Geerling RH, Williams AD, Bamroongsuk V, Toia D, Krum H, Hare DL. Moderate-intensity resistance exercise training in patients with chronic heart failure improves strength, endurance, heart rate variability, and forearm blood flow. J Card Fail. 2004;10:21-30.
  • Krum H, Liew D. Eplerenone in the treatment of chronic heart failure. Exp Rev Cardiovasc Ther. 2004 May;2(3):315-20
  • Krum H, Tonkin A, Piterman L. Bush telegraph. Improving outcomes for rural and remote patients with chronic heart failure. Aust Fam Physician. 2004;33:76-7
  • Krum H, Liew D. A feeling in the waters: diagnosis of heart failure using urinary natriuretic peptides. Clin Sci (Lond). 2004;106:111-2.
  • Krum H, Liew D, Aw J, Haas SJ. Cardiovascular effects of selective cyclooxygenase-2 inhibitors. Exp Rev Cardiovasc Ther. 2004Mar;2(2):265-70

 2003

  • Ashton E, Liew D, Krum H. Should patients with chronic heart failure be treated with statins? Heart Failure Monitor 2003;3(3):82-86.
  • Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, et al, for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effects of initiating carvedilol in patients with severe chronic heart failure. JAMA 2003; 289(6):712-718.
  • Krum H, Gilbert RE. Urotensin II: a new player in vascular and myocardial disease? Clin Sci 2003;103:65-67.
  • Krum H, Liew D. Recent advances in the management of chronic heart failure. Aust Family Physician 2003;32:39-43.
  • Krum H, Liew D. New developments in the pharmacological treatment of chronic heart failure. Expert Opin Investig Drugs 2003;12(5):751-757.
  • Krum H, Liew D. Current status of endothelin blockade for the treatment of cardiovascular and pulmonary vascular disease. Current Opinion in Invest Drugs 2003;4:298-302.
  • Krum H. Beta-blockers in chronic heart failure: What have we learned? What do we still need to know? Current Opinion in Pharmacology 2003;3:168-174.
  • Krum H. Using bisoprolol and carvedilol in chronic heart failure. Medicine Today 2003;4(33)79-80.
  • Liew D, Martin J, Krum H. Eplerenone Pharmacia. Current Opinion in Investigational Drugs 2003;4:316-322.
  • Nelson MR, Reid CM, Krum H, Ryan P, Wing LMH, McNeil JJ, on behalf of the Management Committee, Second Australian National Blood Pressure Study. Short-term predictors of maintenance of normotension after withdrawal of antihypertensive drugs in the Second Australian National Blood Pressure Study (ANBP2), Am J Hypertension 2003;16:39-45.

2002

  • Berakis A, Williams TJ, Naughton MT, Martin JH, Muhlmann M, Krum H. Altered sympathetic and parasympathetic activity in lung transplantation patients at rest and following autonomic perturbation. Chest 2002;122(4):1192-9.
  • Howes LG, Krum H. Selective cyclo-oxygenase-2 inhibitors and myocardialinfarction: how strong is the link? Drug Safety 2002;25(12):829-35.
  • Krum H, Nolly H, Workman D, Weizhong He, Roniker B, Krause S, Fakouhi K. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002;40:117-123.
  • Krum H, McMurray JJ. Statins and chronic heart failure: Do we need a large-scale outcome trial? J Am Coll Cardiology 2002;39:1567-73.
  • Krum H, Roger S. Left ventricular hypertrophy in chronic renal failure patients. Nephrology 2002;7:S640S66.
  • Liew D, Krum H. Chronic heart failure. 2002; Australian Doctor, 15 March, I-VIII. Liew D, McNeil JJ, Peeters A, Lim SS, Vos T. Epidemiological modelling (including economic modelling) and its role in preventive drug therapy. MJA 2002; 177:364-367.
  • Liew D, Krum H. Diastolic heart failure in the elderly. Medicine Today 2002;3:44-50.
  • Liew D, Krum H. The role of aldosterone receptor blockade in the management of cardiovascular disease. Current Opinion in Investigational Drugs 2002;3(10):1468-1473.
  • Martin J, Krum H. Role of Valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease. Pharmacological Research 2002; 46(3):203-212.
  • Martin P, Ninio D, Krum H. Effect of endothelin blockade on basal and stimulated forearm blood flow in patients with essential hypertension. Hypertension 2002;39:821-824.
  • Nelson MR, Reid CM, Krum H, Muir T, Ryan P, McNeil JJ. Predictors of normotension on withdrawal of antihypertensive drugs in elderly patients: prospective study in second Australian National Blood Pressure Study Cohort. BMJ 2002:325.
  • Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ. Comparison of omapatrilat and enalapril in patients with chronic heart failure. The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:21-27.
  • Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 2002;106(17):2194-9.
  • Sondermeijer HP, van Marle AGJ, Kamen P, Krum H. Acute effects of caffeine on heart rate variability. Am J Cardiol 2002;90:906-907.

2001

  • Krum H. New and emerging pharmacological strategies in the management of chronic heart failure. Current Opinion in Pharmacology 2001,11:126-133.
  • Krum H, Denver R, Tzanidis A, Martin P. Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure. Heart Failure Reviews: 2001:6;341-352.
  • Krum H, Tonkin A, Jelinek M, Harris M, McNeil J, Hunt D, Kaye D, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Chronic Heart Failure Clinical Practice Guidelines Writing Panel. Guidelines for management of patients with chronic heart failure in Australia. MJA 2001;74:459-466.
  • Krum H. New and emerging pharmacological strategies in the management of chronic heart failure. Current Opinion in Pharmacology 2001, 1:126-133.
  • Krum H, Tonkin A, Currie R, Djundjek R, Johnston C. Chronic heart failure in Australian general practice: The Cardiac Awareness Survey and Evaluation (CASE) Study. MJA, 2001;174;439-444.
  • Martin J, Krum H. Eplerenone GD Searle & Co. Current Opinion in Investigational Drugs 2001;2(4);521-524.
  • Martin J, Krum H. The Heart Failure Journal Club: a review of publications on heart failure in American Heart Journal. European J of Heart Failure 2001;3:125-137.
  • Nelson M, Reid C, Krum H and McNeil J. A systematic review of subject baseline characteristics and study criteria as predictors of maintenance of Normotension after withdrawal of antihypertensive drugs. American Journal of Hypertension 2001;14(2): 98-105.
  • Nelson MR, McNeil JJ, Peeters A, Reid CM, Krum H. PBS/RPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension in Australia, 1994-1998. MJA, 2001;174(11):565-568.
  • Packer M, Coats, A, Fowler M, Katus H, Krum H, Mohacsi P et al. Effect of carvedilol on survival in severe chronic heart failure. New Engl J Med, 2001;344:1651-8.
  • Tzanidis A, Lim S, Hannan RD, See F, Ugoni AM, Krum H. Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: Possible role of transforming growth factor beta-1. J Mol Cell Cardiol, 2001;33:969-981.